Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 6:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 817–840 of 26,651 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CTRL Clear all

Conditions: Cystic Fibrosis
Interventions: BIIL 283 BS (Amelubent); Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 6 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 35
States / cities: Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 30 more

Conditions: Postoperative Pain, Inflammation, Osteoarthritis
Interventions: Dexamethasone 10 mg, Dexamethasone 20 mg, Standard multimodal pain management regimen, Placebo; Drug
Lead sponsor: Thomas L Bradbury; Other
Eligibility: 18 Years to 100 Years
Enrollment: 1 participant
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Cutaneous T-Cell Lymphoma
Interventions: SGX301 (synthetic hypericin), Placebo; Drug
Lead sponsor: Soligenix; Industry
Eligibility: 18 Years and older
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 33
States / cities: Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 27 more

Conditions: Healthy Volunteers
Interventions: PRT064445/Enoxaparin, Placebo/Enoxaparin, Placebo; Combination Product · Drug
Lead sponsor: Portola Pharmaceuticals; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2015
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Preterm Premature Rupture of Membranes
Interventions: indomethacin; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 15 Years to 50 Years · Female only
Enrollment: 116 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Post Herpetic Neuralgia
Interventions: Pregabalin, placebo; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 82
States / cities: Gulf Shores, Alabama • Chandler, Arizona • Phoenix, Arizona + 62 more

Conditions: Episodic Migraine Headache
Interventions: LBR-101 High Dose, LBR-101 Low Dose, Placebo; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 63
States / cities: Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more

Conditions: Ascites, Liver Cirrhosis
Interventions: satavaptan (SR121463B); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 110 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2005
U.S. locations: 1
States / cities: Bridgewater, New Jersey

Conditions: Intercritical Gout
Interventions: Placebo, Rilonacept 80 mg, Rilonacept 160 mg; Other · Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 241 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 67
States / cities: Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 61 more

Conditions: Cesarean Section Complications, Opioid Use
Interventions: Preoperative Genotyping; Diagnostic Test
Lead sponsor: Senthil Sadhasivam; Other
Eligibility: 18 Years and older · Female only
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 4
States / cities: Indianapolis, Indiana • St Louis, Missouri • Pittsburgh, Pennsylvania

Conditions: Schizophrenia
Interventions: AZD8529, Placebo to match AZD8529; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Severe Spasticity
Interventions: intrathecal baclofen; Drug
Lead sponsor: MedtronicNeuro; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 9
States / cities: Irvine, California • Washington D.C., District of Columbia • Doral, Florida + 6 more

Conditions: Infant, Newborn, Infant, Low Birth Weight, Infant, Small for Gestational Age, Infant, Premature, Retinopathy of Prematurity, Bronchopulmonary Dysplasia (BPD)
Interventions: Inositol lower volume, Inositol mid-level volume, Inositol high volume, Placebo low volume; Drug
Lead sponsor: NICHD Neonatal Research Network; Network
Eligibility: 12 Hours to 72 Hours
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2013
U.S. locations: 17
States / cities: Birmingham, Alabama • Palo Alto, California • New Haven, Connecticut + 13 more

Conditions: Anemia, Iron Deficiency, Hyperphosphatemia, Renal Insufficiency, Chronic, Renal Anemia, Disease Progression, Cardiovascular, Iron
Interventions: Ferric Citrate 1 GM Oral Tablet [AURYXIA], Placebo; Drug
Lead sponsor: USRC Kidney Research; Network
Eligibility: 18 Years and older
Enrollment: 289 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 23
States / cities: Pine Bluff, Arkansas • Chula Vista, California • El Centro, California + 16 more

Conditions: Crohn's Disease
Interventions: Mirikizumab, Ustekinumab, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 15 Years to 80 Years
Enrollment: 1,158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 140
States / cities: Birmingham, Alabama • Dothan, Alabama • Guntersville, Alabama + 113 more

Conditions: Diabetes Mellitus, Type 2
Interventions: JTT-662, Placebo; Drug
Lead sponsor: Shionogi Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Opioid-use Disorder, Medication Assisted Treatment, Chronic Pain
Interventions: Psychosocial Pain Management (PPMI), Enhanced Usual Care (EUC); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 2
States / cities: Ann Arbor, Michigan

Conditions: Type 2 Diabetes
Interventions: Lysulin; Dietary Supplement
Lead sponsor: Juraj Koska; Federal
Eligibility: 21 Years to 75 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 2
States / cities: Phoenix, Arizona

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: AEVI-001, Placebo; Drug
Lead sponsor: Aevi Genomic Medicine, LLC, a Cerecor company; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Wayne, Pennsylvania

Conditions: Disruptive Behavior, Attention-deficit Hyperactivity, Oppositional Defiant Disorder
Interventions: Garmin; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 3 Years to 99 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Overweight, Obesity
Interventions: Smart Moms Intervention; Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 3 Years and older
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Angioedema
Interventions: Icatibant, Placebo; Drug
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Chronic Kidney Disease, Metabolic Acidosis
Interventions: Sodium bicarbonate, Placebo; Drug
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 19 Years and older
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: The Bronx, New York • Cleveland, Ohio

Conditions: Hemophilia
Interventions: rFVIII; Drug
Lead sponsor: Craig Seaman; Other
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

Efficacy and Safety of 24 Weeks of Oral Treatment With BIIL 284 BS in Adult and Pediatric Patients

Steroids in Total Knee Arthroplasty

FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)

Phase 2 Healthy Volunteer Study to Evaluate the Ability of PRT064445 to Reverse the Effects of Several Blood Thinner Drugs on Laboratory Tests (Module 3 of 4)

Indomethacin Versus Placebo in Women With Preterm Premature Rupture of Membranes (PPROM)

Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Postherpetic Neuralgia

A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine

Satavaptan Dose-Ranging Study in Hyponatraemic Patients With Cirrhotic Ascites

PREventative Study Against URate-lowering Drug-induced Gout Exacerbations 1

Personalized Perioperative Analgesia Platform (PPAP) for Cesarean Section

The Effects AZD8529 on Cognition and Negative Symptoms in Schizophrenics

SISTERS: Spasticity In Stroke Study - Randomized Study

Multi-dose Pharmacokinetics and Dose Ranging of Inositol in Premature Infants (INS-2)

Ferric Citrate for the Prevention of Renal Failure in Adults With Advanced Chronic Kidney Disease

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Study to Evaluate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of JTT-662 in Subjects With Type 2 Diabetes

Psychosocial Pain Management to Improve Opioid Use Disorder Treatment Outcomes

The Effect of Lysulin on Glycemic Control and Advanced Glycation

PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations

Monitoring of Sleep and Behavior of Children 3-7 Years Old Receiving Parent-Child Interaction Therapy With the Help of Artificial Intelligence

Trial of a Sugar-Sweetened Beverage Intervention in Overweight Mothers and Their Children Ages 3-5

Subcutaneous Treatment With Icatibant for Acute Attacks of Hereditary Angioedema

Alkali Therapy in Chronic Kidney Disease

Weight-based Dosing in Hemophilia A